Marksans Pharma updates on USFDA inspection at Verna, Goa manufacturing facility

Bayer strengthens pharma portfolio with new cardiology drug acoramidis

Acquisition of exclusive commercialization rights for European markets

Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards

NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate

Study efficacy measures will include the expression of dystrophin protein and motor function.

Marksans Pharma announces USFDA approval for Famotidine Tablets

Marksans' OTC Famotidine Tablets USP are acid reducers

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK

Marksans Pharma raises Rs. 372.40 crores

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.